2 results
Approved WMOWill not start
Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-…
Approved WMOCompleted
The objective of this study is to prove that a single injection of PRP in the CEO decreases pain and duration of the condition in patients with chronic lateral epicondylitis compared to injection with lidocaine and corticosteroids.The specific…